<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302471</url>
  </required_header>
  <id_info>
    <org_study_id>0429-011</org_study_id>
    <secondary_id>MK0429-011</secondary_id>
    <secondary_id>2006_013</secondary_id>
    <nct_id>NCT00302471</nct_id>
  </id_info>
  <brief_title>MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)</brief_title>
  <official_title>A Phase I, Randomized, Multicenter, Double-Blind Study of MK0429 in the Treatment of Men With Hormone Refractory Prostate Cancer and Metastatic Bone Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This two part study will evaluate the safety and tolerability of MK0429 in addition to
      assessing it's pharmacokinetic profile and pharmacodynamic response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of 4 weeks of MK0429 therapy.</measure>
    <time_frame>up to 14 days following last dose of medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Pharmacokinetic profile of MK0429 and pharmacodynamic responses to treatment of MK0429</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Pharmacokinetic profile of MK0429 [Time frame 4 weeks] and pharmacodynamic responses to treatment of MK0429 [Time frame 8 weeks]</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>1600 mg twice a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0429</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg twice a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0429</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg twice a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0429</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg twice a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0429</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK0429</intervention_name>
    <description>Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.
Disease.</description>
    <arm_group_label>1600 mg twice a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK0429</intervention_name>
    <description>Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.</description>
    <arm_group_label>200 mg twice a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK0429</intervention_name>
    <description>Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.</description>
    <arm_group_label>800 mg twice a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK0429</intervention_name>
    <description>Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.</description>
    <arm_group_label>400 mg twice a day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients must have:

               -  Prostate cancer

               -  Bone metastases without symptoms

               -  Lack of response to hormone therapy as evidenced by a rising PSA or clinical
                  progression

        Exclusion Criteria:

          -  Prostate cancer-related bone pain

          -  Previously received bisphosphonate therapy (e.g. zoledronate)

          -  Received any investigational treatment within the last 30 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>France</country>
    <country>New Zealand</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Rosenthal MA, Davidson P, Rolland F, Campone M, Xue L, Han TH, Mehta A, Berd Y, He W, Lombardi A. Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia Pac J Clin Oncol. 2010 Mar;6(1):42-8. doi: 10.1111/j.1743-7563.2009.01266.x.</citation>
    <PMID>20398037</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2006</study_first_submitted>
  <study_first_submitted_qc>March 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2006</study_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

